Competition & Peer Data API & CSV Delivery Connect to AI Assistant via MCP

Cadence Pharmaceuticals Inc's Competitiveness

A competitive positioning analysis and financial ratio benchmarking of Cadence Pharmaceuticals Inc (CADX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q4 2013
Competitors Tracked
-
Publicly traded peers
Peer Group Market Share
100.00 %
vs 100.00 % a year ago
Revenue Growth Y/Y
105.62 %
Q4 2013
Net Margin
248.95 %
Q4 2013

Key Findings: Cadence Pharmaceuticals Inc vs Its Competitors

  • TTM: Trailing 12-month revenue of 113M vs -M combined for tracked competitors (100.0% combined share).
  • Trending: Latest-quarter revenue run-rate is accelerating (+25.5% annualized vs trailing 12 months).
  • Peer revenue share: Cadence Pharmaceuticals Inc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.

Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).

CADX Sales vs. its Competitors, Q4 2013

Cadence Pharmaceuticals Inc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.

API endpoints for this dataset
https://api.csimarket.com/api/v1/companies/CADX/competitors
https://api.csimarket.com/api/v1/companies/CADX/relationships
https://api.csimarket.com/api/v1/companies/CADX/similar
Programmatic access for models, analytics, and integration workflows.

For context: the Biotechnology & Pharmaceuticals industry grew revenue 21.1% year over year, combined, vs 105.6% for Cadence Pharmaceuticals Inc. Cadence Pharmaceuticals Inc's share of combined industry revenue moved from 0.05% to 0.08%, a gain of 0.03 percentage points.

Cadence Pharmaceuticals Inc's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity Profitable Expanding Above Industry Growth Distressed
Cadence Pharmaceuticals Inc Yes Yes Yes No
Similar Growth & Profitability (8) 62.50 % (5 of 8) 100.00 % (8 of 8) 100.00 % (8 of 8) 0.00 % (0 of 6)

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

Market Share of the Peer Group, Q4 2013

100%market share
  • Cadence Pharmaceuticals Inc100.0%
  • Competitors combined0.0%

Share of combined quarterly revenue of Cadence Pharmaceuticals Inc and its 0 tracked competitors.

See Cadence Pharmaceuticals Inc's full market share breakdown »

CADX Stock Performance relative to its Competitors

CADX Competitors (weighted) Percent change over the selected range

CADX Stock Performance relative to Similar Growth & Profitability Competitors

CADX Similar Growth & Profitability Competitors (equal-weighted, 8) Percent change over the selected range
Get the full CSIMarket dataset: Subscribe API Connect Your AI